| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.78B | 37.56B | 36.35B | 36.06B | 35.45B | 35.98B |
| Gross Profit | 14.82B | 18.43B | 18.23B | 18.15B | 17.73B | 16.80B |
| EBITDA | 12.05B | 11.22B | 13.21B | 12.38B | 11.86B | 11.11B |
| Net Income | -168.00M | -66.00M | -471.00M | 393.00M | 1.26B | -1.02B |
Balance Sheet | ||||||
| Total Assets | 101.17B | 98.76B | 94.56B | 95.06B | 94.22B | 97.84B |
| Cash, Cash Equivalents and Short-Term Investments | 3.14B | 2.58B | 2.71B | 3.13B | 5.04B | 4.62B |
| Total Debt | 59.25B | 53.94B | 54.19B | 51.65B | 49.22B | 60.56B |
| Total Liabilities | 93.77B | 87.24B | 84.86B | 82.30B | 78.74B | 84.28B |
| Stockholders Equity | 4.23B | 7.49B | 2.48B | 11.44B | 14.36B | 9.93B |
Cash Flow | ||||||
| Free Cash Flow | 6.51B | 3.08B | 5.32B | 3.43B | 1.78B | 5.57B |
| Operating Cash Flow | 8.68B | 10.63B | 13.35B | 10.34B | 9.70B | 12.70B |
| Investing Cash Flow | -2.33B | -7.70B | -7.46B | -6.01B | -7.62B | -7.54B |
| Financing Cash Flow | -6.50B | -3.26B | -6.27B | -5.83B | -1.57B | -6.47B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | HK$5.26B | 11.00 | 9.18% | 6.79% | 0.52% | 2.07% | |
73 Outperform | HK$9.29B | 10.14 | 8.67% | 7.46% | -0.62% | -5.10% | |
72 Outperform | HK$89.02B | 17.27 | 14.75% | 2.86% | 2.33% | 2.41% | |
67 Neutral | HK$621.41B | 13.05 | 7.66% | 5.40% | 0.53% | 5.28% | |
60 Neutral | $48.67B | 4.58 | -11.27% | 4.14% | 2.83% | -41.78% | |
50 Neutral | HK$9.33B | 42.12 | 8.55% | 5.45% | 4.48% | 1820.51% | |
49 Neutral | HK$42.66B | -150.55 | ― | 1.68% | 4.26% | 36.68% |
PCCW, HKT Trust and HKT have entered into a new set of continuing connected transaction agreements with the FWD Group covering telecommunications, insurance-related, and branding and marketing services for a further three-year term ending 31 December 2028, replacing existing arrangements that expire at the end of 2025. Because FWD is controlled by PCCW and HKT executive Richard Li, the deals are classified as connected transactions under Hong Kong listing rules, with the applicable transaction size ratios falling between 0.1% and 5% for most of the framework agreements, triggering announcement, reporting and annual review requirements but exempting them from independent shareholders’ approval, while the branding and marketing framework with HKT is small enough to be fully exempt from disclosure and review obligations.
The most recent analyst rating on (HK:0008) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on PCCW Limited stock, see the HK:0008 Stock Forecast page.
PCCW Limited has announced the issuance of 287,792 new shares under its General Mandate to satisfy the vesting of awards granted to selected employees under the PCCW Subscription Scheme. This issuance represents a minimal percentage of the total shares in issue and is intended to reward employees without requiring shareholder approval. The shares will be held in trust and transferred to employees at no cost upon meeting certain conditions, with the company funding the entire subscription cost.
The most recent analyst rating on (HK:0008) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on PCCW Limited stock, see the HK:0008 Stock Forecast page.
PCCW Limited’s Board of Directors has revised and approved the terms of reference for its Audit Committee, emphasizing the enhancement of financial reporting objectivity, risk management, and corporate governance. The Committee, composed of non-executive directors, is tasked with maintaining a strong relationship with external auditors and ensuring compliance with relevant laws, which is expected to bolster the company’s operational integrity and stakeholder confidence.
The most recent analyst rating on (HK:0008) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on PCCW Limited stock, see the HK:0008 Stock Forecast page.
PCCW Limited has revised the terms of reference for its Nomination Committee, which plays a crucial role in ensuring a fair and transparent process for appointing and re-appointing directors. The committee is tasked with maintaining a diverse and skilled board that aligns with the company’s strategic needs. This revision aims to enhance the committee’s effectiveness in identifying qualified candidates, assessing director independence, and promoting board diversity, thereby strengthening PCCW’s governance framework.
The most recent analyst rating on (HK:0008) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on PCCW Limited stock, see the HK:0008 Stock Forecast page.